[HTML][HTML] Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai… - … England Journal of …, 2020 - Mass Medical Soc
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai… - New England Journal …, 2020 - research.rug.nl
BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot… - New England Journal …, 2020 - cir.nii.ac.jp
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
PK Paik, E Felip, R Veillon, H Sakai… - New England …, 2020 - scholars.northwestern.edu
BACKGROUND A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
[PDF][PDF] Cortot
PK Paik, E Felip, R Veillon… - B., Garassino, MC … - scholarlypublications …
BACKGROUND A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
[PDF][PDF] Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot… - 2020 - core.ac.uk
BACKGROUND A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
PK Paik, E Felip, R Veillon, H Sakai… - … England Journal of …, 2020 - yonsei.elsevierpure.com
BACKGROUND A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai… - The New England …, 2020 - pubmed.ncbi.nlm.nih.gov
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot… - 2020 - ir.ymlib.yonsei.ac.kr
Background: A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
PK Paik, E Felip, R Veillon, H Sakai… - The New England …, 2020 - europepmc.org
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …
oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer …